- Home
- SEER vs VERU Comparison
SEER vs VERU Comparison
Compare SEER & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- VERU
- Stock Information
- Founded
- SEER 2017
- VERU 1971
- Country
- SEER United States
- VERU United States
- Employees
- SEER N/A
- VERU N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- VERU Health Care
- Exchange
- SEER Nasdaq
- VERU Nasdaq
- Market Cap
- SEER 114.3M
- VERU 107.2M
- IPO Year
- SEER 2020
- VERU 1990
- Fundamental
- Price
- SEER $2.31
- VERU $0.58
- Analyst Decision
- SEER Hold
- VERU Strong Buy
- Analyst Count
- SEER 1
- VERU 4
- Target Price
- SEER $3.00
- VERU $4.00
- AVG Volume (30 Days)
- SEER 276.5K
- VERU 996.7K
- Earning Date
- SEER 11-06-2024
- VERU 12-06-2024
- Dividend Yield
- SEER N/A
- VERU N/A
- EPS Growth
- SEER N/A
- VERU N/A
- EPS
- SEER N/A
- VERU N/A
- Revenue
- SEER $14,608,000.00
- VERU $14,091,909.00
- Revenue This Year
- SEER N/A
- VERU N/A
- Revenue Next Year
- SEER $40.36
- VERU N/A
- P/E Ratio
- SEER N/A
- VERU N/A
- Revenue Growth
- SEER N/A
- VERU N/A
- 52 Week Low
- SEER $1.47
- VERU $0.36
- 52 Week High
- SEER $2.50
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- SEER 63.86
- VERU 24.06
- Support Level
- SEER $2.15
- VERU $0.72
- Resistance Level
- SEER $2.50
- VERU $0.83
- Average True Range (ATR)
- SEER 0.13
- VERU 0.06
- MACD
- SEER 0.03
- VERU -0.02
- Stochastic Oscillator
- SEER 68.85
- VERU 1.38
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.